An investigator initiated pilot study of transcutaneous auricular vagal nerve stimulation (taVNS) in mild to moderate Parkinson's disease (PD).
We will assess whether nerve stimulation done on the surface of the skin, (called transcutaneous vagus nerve stimulation (taVNS)) is safe and effective in people with Parkinson's Disease (PD). A small electrical stimulator will be used to deliver electric pulses to a small portion of the left ear of the study participants. Participants will be assigned by chance to either 2 weeks of treatment with real taVNS, or a sham stimulation. The investigator will rate PD motor and cognitive symptoms before, during, and after the 2-week cycle. The investigators will also perform a number of blood and eye movement tests to check for the effectiveness of the stimulation, and perform regular safety checks.
The purpose of this study is to determine if a drug called Nilotinib is safe, if it can be tolerated by patients with PD and to learn if Nilotinib has the possibility of effectively treating PD symptoms. Nilotinib has been approved by the Food and Drug Administration (FDA) to treat certain types of cancer (leukemia) but is considered investigational in this study because it has not been approved for treating PD.
In this study, we are comparing two doses (150mg or 300mg) of Nilotinib to placebo (a pill that looks like the study drug but does not have any active medication in it, like a sugar pill). If you are eligible and choose to be in the study you will be randomly assigned to one of three groups, either:
? 150mg Nilotinib
? 300mg Nilotinib
All three groups will take two pills of the assigned type each day by mouth. ?Randomly' means that the group you are placed in is determined by chance (like tossing a coin). You will have a 2:1 chance of receiving Nilotinib. Neither you nor the researchers will know whether you are taking Nilotinib or placebo.
About 100 individuals will be interviewed and assessed, and 75 people will be asked to participate in this study at 25 clinics across the United States. Approximately 6 participants will be asked to participate in the study at MUSC.
This study will assess the effectiveness, safety and tolerability of Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) compared to Immediate Release Carbidopa/Levodopa (IR CD/LD) (Sinemet) in patients with fluctuating Parkinson's disease (PD).
This study examines eye movements and the pupil's response to light in progressive supranuclear palsy (PSP), comparing to Parkinson's disease and control subjects without neurological disease. Computerized measures of eye movements and pupil changes will be used. Subjects will also receive an eye exam to rule out other eye diseases. The goal of this study is to use subtle changes in eye movements and the pupil's response to light for earlier diagnosis of PSP.
This study will examine changes in brain architecture that are associated with vascular parkinsonism, in comparison to Parkinson's disease. We will do this by using advanced imaging techniques to compare brain structure between subjects with vascular parkinsonism and Parkinson's disease.
You are invited to volunteer for a research study if you have been diagnosed with Parkinson's Disease (PD) Stage 1-3.
This study will examine whether a kickboxing regime called "Rock Steady Boxing" helps improve cognitive dysfunction (thinking problems) in subjects with Parkinson's disease. "Rock Steady Boxing" is a fairly recent intervention for PD exercise rehabilitation.This program incorporates elements of aerobic exercise, with range of motion, visual spatial awareness, endurance, speed, agility, voice strengthening, and cognitive tasks. Your are eligible to participate if you plan to undergo Rock Steady Boxing as part of your own personal health plan, or you have indicated that you exercise regularly, but you do not intend to start Rock Steady Boxing.
This is a prospective, observational, naturalistic study to assess the efficacy of dopaminergic medications in reducing depressive symptoms, as measured by validated self-rating depression scales, and compared to initiation of alternative dopaminergic therapies (e.g. L-dopa vs. DA vs. MAO-B inhibitors).
Ascertainment of a true antidepressant effect of Pramipexole, Rotigotine and/or Ropirinole (or of any of the other dopaminergic agents) would have an impact on the manner in which this disabling problem is currently addressed.
In this study, we seek to collect data on the putative antidepressant and anti-apathy effect of dopaminergic medications (L-dopa and non-ergot DA, RPN, PPX, and rotigotine [RTG]), given under naturalistic conditions to address motor impairment (not mood disorders), on PD patients, as measured by validated depression and apathy rating scales, and comparing it to changes to L-dopa and other anti-parkinsonian agents.
In this study, we plan to record electric fields (EF) in the brain while transcranial direct current stimulation (tDCS) is applied through the scalp. We will include patients who are scheduled to undergo deep brain stimulation (DBS) procedure to participate in the study, after explaining the procedures, answering any questions and receiving informed consent. The study might prolong the duration of the DBS procedure by a few minutes because of the time taken to apply tDCS. However, no other deviations from standard DBS procedures will be made. That is, no additional DBS electrode penetrations will be performed for research purposes - we will record from DBS electrodes that are being inserted exclusively as a part of clinical care.
This is a prospective, multi-center, open-label, Phase 3 study in Levodopa responsive PD patients with motor fluctuations, designed to evaluate the long-term safety, tolerability and efficacy of APL-130277. APL-130277 is being evaluated as a "rescue" treatment for OFF episodes.
The overall number of subjects is not pre-specified as this is an extension
Patients who have completed any of the following studies: CTH-201,
CTH-203, CTH-300, CTH-301, or CTH-302 will be eligible to enroll into
this study. In addition, approximately one hundred (100) de novo patients
will also be enrolled.
It is known that the pupil's response to light is abnormal in advanced Parkinson's disease. This study will explore whether signs of pupil dysfunction may be a biomarker of the presence of early Parkinson's disease (before medications are used to treat the condition.) The study will also examine a new and simplified way of measuring the pupil's response to light, using a smart phone application, to hopefully be used as a screening/tracking measure in clinical settings in the future. To complete this study, we are recruiting both healthy adults age 30-80 years old as well as individuals with early signs of Parkinson's disease that have not yet been treated with medication for this condition. The study required approximately 20-30 minutes to complete on MUSC's campus (compensation not included.)